



IFW

Patent Application  
Attorney Docket No. PC25489A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 13<sup>th</sup> day of September 2004

By

*Irene Grantham*  
(Signature of person mailing)

Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gillian Munro Burgess, et al.

APPLICATION NO.: 10/799,191 : Examiner: To Be Assigned

FILING DATE: 03/12/2004 : Group Art Unit: 1614

TITLE: TREATMENT OF TYPE 1 DIABETES WITH PDE5 INHIBITORS

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: Sept. 13, 2004  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof  
Martha G. Munchhof  
Attorney for Applicant(s)  
Reg. No. 47,811

[illegible]